Table 1.
Risk classification systems of PCa
| D’Amico classification5 | ||
|---|---|---|
| Low risk | Gleason score ≤6, PSA<10 µg/L, clinical stage ≤T2a | |
| Intermediate risk | Gleason score ≤7, PSA 10–20 µg/L, clinical stage ≤T2b | |
| High risk | Gleason score >7, PSA>20 µg/L, clinical stage T2c | |
|
| ||
| CAPRA score*,6 | ||
|
| ||
| Level | Points | |
| PSA at diagnosis | 2–6.0 µg/L | 0 |
| 6.1–10 µg/L | 1 | |
| 10.1–20 µg/L | 2 | |
| 20.1–30 µg/L | 3 | |
| >30 µg/L | 4 | |
| Age at diagnosis | <50 years old | 0 |
| ≥50 years old | 1 | |
| T stage | T1/T2 | 0 |
| T3 | 1 | |
| Percent of biopsy cores involved with cancer | <34% | 0 |
| ≥34% | 1 | |
|
| ||
| NCCN classification7 | ||
|
| ||
| Very low risk | Gleason score ≤6, PSA<10 µg/L, Stage T1c, not more than two cores with cancer, <50% of core involved with cancer, and PSA density <0.15 | |
| Low risk | Gleason score ≤6, PSA<10 µg/L, Stage T1c or T2a | |
| Intermediate risk | Gleason score 7, PSA 10–20 µg/L, Stage T2b–T2c | |
| High risk | Gleason score ≥8, PSA≥20 µg/L, Stage T3a | |
Note:
*
The CAPRA score is the sum of the points assigned for each variable and classifies patients into low, intermediate, and high risk. A CAPRA score of 0 to 2 indicates low-risk; a CAPRA score of 3 to 5 indicates intermediate-risk; and a CAPRA score from 6 to 10 indicates high-risk.
Abbreviations: CAPRA, Cancer of the Prostate Risk Assessment; NCCN, National Comprehensive Cancer Network; PCa, prostate cancer; PSA, prostate-specific antigen.